The company said a late-stage study of its insulin Degludec showed it “significantly reduces risk” of hypoglycemia during the night compared with glargine.

OBJECTIVE Early use of insulin after diagnosis of type 2 diabetes is met with resistance because of associated weight gain, hypoglycemia, and fear of decreased compliance and quality of life (QoL).

Overall, hypoglycemia episodes were 7% less likely with long-acting insulin preparations. In terms of severe and nocturnal episodes, such preparations cut the risks by 27% and 30%, respectively.